Navigation Links
Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
Date:5/27/2009

NEW YORK, May 27 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. ("Biostar" or the "Company") (OTC Bulletin Board: BSPM) today reported financial results for the three months ended March 31, 2009.

The Company reported revenue of $7,447,664 for the quarter ended March 31, 2009 as compared to $6,810,259 during the first quarter of 2008. Net Income for the first quarter 2009 was $1,829,032, or $0.08 per share on a fully diluted basis, versus $1,821,130, or $0.08 per share, respectively, for 2008.

The increase in revenue reflects an increase in sales for four of Biostar's five state approved drugs. The sales in the four products increased mainly due to the continued implementation of the "Blue Sea" project which markets directly to consumers in the PRC's rural area through retail pharmacies.

Net income did not increase at the same rate as sales did, primarily due to the increase in Selling General and Administrative ("SG&A") expenses as a percentage of sales. SG&A accounted for 33% of sales in the first quarter of 2009 as compared to 30% for the first quarter of 2008, which reflects an increase in staff and marketing budget and expenditure which is expected to benefit the Company's sales effort going forward. This increase in SG&A was partially offset by a decrease in the cost of raw materials, as the Sichuan Province is recovering from the devastating earthquake of 2008, and herbal supplies from the province and their prices have returned to their normal levels.

Ronghua Wang, Chairman and Chief Executive Officer of the Company, stated, "I am pleased that we have been able to report continued growth in revenues as we implement our plans to establish Biostar as a leading provider of over-the-counter and prescription treatments for disease and chronic conditions throughout the People's Republic of China. The investments we are making in marketing, staff and i
'/>"/>

SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
2. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
3. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
4. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
5. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
6. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
7. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
8. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
9. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
10. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
11. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  Dyadic International, Inc. ("Dyadic") ... patented and proprietary technologies are used to discover, ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... "Tom" Dubinski as Vice President and Chief Financial ... financial and information technology operations for Dyadic and ...
(Date:7/30/2014)... July 30, 2014  AtheroNova Inc. (OTCBB: AHRO), ... development of compounds to safely regress atherosclerotic plaque ... that its partner, CardioNova, has accomplished first dosing ... with AtheroNova,s lead compound, AHRO-001.  This Phase 1b ... Phase 1 safety trial completed in February 2014, ...
(Date:7/30/2014)... 2014 Connecticut Center for Advanced Technology, ... East Hartford, Conn., was awarded a Rural Business Enterprise ... project that will determine the feasibility of implementing an ... USDA Rural Development provided $53,000 for CCAT under the ... phase of the feasibility study in fiscal year 2014. ...
(Date:7/30/2014)... July 30, 2014 Immunology ... leading Immunologists, Principle Investigators, scientists in the field, ... Malemud, Professor at Case Western Reserve University School ... keynote address on “The effects of recombinant ... of matrix metalloproteinase-9”. Arya Biragyn, a Senior investigator ...
Breaking Biology Technology:Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... Revenue Increased 61% Compared to 3Q06 to $43.5 Million in 3Q07 -,- 3Q07 ... ... Share - - Company Provides Financial ... Oriental,Bioengineering, Inc. (NYSE: AOB ), a leading manufacturer and distributor of,plant-based pharmaceutical ...
... ... up 10%, Compared to Third Quarter 2006 FFO Per Share (Diluted) of ... $1.32 - Third Quarter 2007 Total Revenues up 23%, FFO Available to ... Stockholders up 21% - Third Quarter 2007 Earnings Per Share (Diluted) ...
... Bruker Daltonics today,announced the availability of its ... poster presentations on its website at, http://www.bdal.com . ... Characterization and General Mass Spectrometry, -- Novel ... Peptide Characterization Poster M103 ...
Cached Biology Technology:American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 2American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 3American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 4American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 5American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 6American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 7American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 8Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 2Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 3Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 4Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 5Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 6Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 7Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 8Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 9Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 10Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 11Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 12Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 13Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 14Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 15Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 16Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 17Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 18Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 19Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 20Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 21Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 22Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 23Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 24Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 25Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 26Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 27Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 28Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 29
(Date:7/30/2014)... map of the carbon stocks stored on land ... and improved methodology used to make the map ... economies. The new carbon map also reveals ... the critical input to studies of deforestation and ... purposes. The technique includes the determination of uncertainty ...
(Date:7/29/2014)... and applications for imaging and manipulation of the brain ... the inspiration behind Neurophotonics , a new peer-reviewed ... and photonics. , The first issue coincides with the ... and a special section features articles that lay out ... that optics and photonics will have on advancing our ...
(Date:7/29/2014)... a restaurant, don,t blame yourself; blame the menu. What ... want and more to do with a menu,s layout and ... over 300 diners, the Cornell study published this month in ... when it comes to what you order for dinner, two ... how you imagine it will taste. , First, any food ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3Menu secrets that can make you slim by design 2
... University scientists are working to determine how neurons are ... disorders like Tuberous Sclerosis Complex (TSC). TSC is ... tumors in the brain and other vital organs and ... impairment that may arise from the abnormal generation of ...
... who invest in their own solar panels for the roof ... the long term but how long will this technology ... up to 25 years to their customers, the manufacturers themselves ... modules must fulfill certain standards, of course, to be approved ...
... fundamental processes in the life of plants because they have ... Leeds researchers. Arabidopsis thaliana also known as thale ... over Europe and Asia, but the small white flower leads ... world. It has become the dominant "model plant" in ...
Cached Biology News:Clemson University study points to possible treatment for brain disorders 2Predicting the life expectancy of solar modules 2Predicting the life expectancy of solar modules 3Model plant misled scientists about multicellular growth 2Model plant misled scientists about multicellular growth 3
...
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
PP2B-Abeta (C-20)...
Biology Products: